Pathologist — Cellular Diagnosis Specialist

Pathologists complete rigorous medical and laboratory training to interpret histological, cytological, and molecular alterations in human biological specimens. When a surgeon or radiologist performs a biopsy or surgical excision, the extracted sample is sent directly to the pathology department. The pathologist oversees tissue preservation, microtome sectioning, and chemical staining before meticulously analysing the structural architecture of the tissue to distinguish between benign abnormalities and malignant growths.

Beyond basic microscopy, contemporary surgical pathologists and molecular pathologists utilise advanced diagnostic assays. They identify tumour subtype, grade the aggressiveness of the cells, confirm whether surgical margins are clear of malignancy, and conduct complex genetic sequencing. Their technical assessments generate the definitive pathology report, which serves as the diagnostic foundation for multidisciplinary cancer conferences and staging.

An accurate diagnosis is the cornerstone of safe, effective cancer care, and that diagnosis originates with the pathologist. A clinical examination or scan can suggest the presence of a tumour, but only a pathologist can confirm malignancy. Their findings dictate whether surgery, chemotherapy, radiotherapy, or targeted medicine is appropriate. A precise histological evaluation prevents misdiagnosis, spares patients from ineffective treatments, and helps assess overall prognosis.

Pathologists perform routine haematoxylin and eosin (H&E) staining, immunohistochemistry (IHC) to detect specific proteins like HER2 or PD-L1, fluorescence in situ hybridisation (FISH), and next-generation sequencing (NGS) to reveal driver mutations, microsatellite instability (MSI), or gene rearrangements in tumour DNA.

Pathologists evaluate every variety of suspected malignancy. Common examples include determining hormone receptor status in breast carcinoma, subtype classification in lung adenocarcinoma, depth of invasion in cutaneous melanoma, Gleason scoring in prostate cancer, and molecular lineage differentiation in complex soft tissue sarcomas and haematological lymphomas.

The pathologist’s findings guide therapeutic selection. Identifying clear surgical margins may prevent redundant re-operations, while finding positive lymph nodes can prompt adjuvant chemotherapy or radiotherapy. Pinpointing actionable biomarkers directly qualifies patients for precision medicines, such as EGFR inhibitors, PARP inhibitors, or immune checkpoint inhibitors.